Endostar Acts As a Pneumonitis Protectant in Patients with Locally Advanced Non-small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2024 Feb 23

PMID 38395838

Authors

Kuifei Chen

Shuling Li

Meng Chen

Zhicheng Jin

Xuefeng Sun

Suna Zhou

Haihua Yang

Affiliations

Soon will be listed here.

Abstract

Background: CCRT is presently the standard treatment for LA-NSCLC. RP is one of the main obstacles to the completion of thoracic radiation therapy, resulting in limited survival benefits in NSCLC patients. This research aims to explore the role of Endostar in the occurrence of grade≥2 RP and clinical curative effect in LA-NSCLC patients.

Methods: This study retrospectively analyzed 122 patients with stage III NSCLC who received CCRT from December 2008 to December 2017, or Endostar intravenous drip concurrently with chemoradiotherapy (Endostar + CCRT group). Standard toxicity of the pneumonitis endpoint was also collected by CTCAE V5.0. We further summarized other available studies on the role of Endostar in the prognosis of NSCLC patients and the incidence of RP.

Results: There were 76 cases in the CCRT group and 46 cases in the CCRT+ Endostar group. In the CCRT+ Endostar group, the occurrence of grade ≥2 RP in patients with V20Gy ≥25% was significantly higher than that in patients with V20Gy < 25% (p = 0.001). In the cohorts with V20Gy < 25%, 0 cases of 29 patients treated with Endostar developed grade ≥2 RP was lower than in the CCRT group (p = 0.026). The re-analysis of data from other available studies indicated that Endostar plus CCRT could be more efficient and safely in the occurrence of grade≥2 RP with LA-NSCLC.

Conclusions: When receiving CCRT for LA-NSCLC patients, simultaneous combination of Endostar is recommended to enhance clinical benefit and reduce pulmonary toxicity.

References

Fahey R, Smoluk G, Ward J . Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721. Int J Radiat Biol Relat Stud Phys Chem Med. 1985; 47(1):23-7. DOI: 10.1080/09553008514550041. View

Antonadou D, Throuvalas N, Petridis A, Bolanos N, Sagriotis A, Synodinou M . Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2003; 57(2):402-8. DOI: 10.1016/s0360-3016(03)00590-x. View

Semrau S, Klautke G, Virchow J, Kundt G, Fietkau R . Impact of comorbidity and age on the outcome of patients with inoperable NSCLC treated with concurrent chemoradiotherapy. Respir Med. 2007; 102(2):210-8. DOI: 10.1016/j.rmed.2007.09.009. View

Dang J, Li G, Zang S, Zhang S, Yao L . Comparison of risk and predictors for early radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with radiotherapy with or without surgery. Lung Cancer. 2014; 86(3):329-33. DOI: 10.1016/j.lungcan.2014.10.005. View

Wu K, Xu X, Li X, Wang J, Zhu L, Chen X . Radiation pneumonitis in lung cancer treated with volumetric modulated arc therapy. J Thorac Dis. 2019; 10(12):6531-6539. PMC: 6344715. DOI: 10.21037/jtd.2018.11.132. View

Tanabe K, Maeshima Y, Ichinose K, Kitayama H, Takazawa Y, Hirokoshi K . Endostatin peptide, an inhibitor of angiogenesis, prevents the progression of peritoneal sclerosis in a mouse experimental model. Kidney Int. 2006; 71(3):227-38. DOI: 10.1038/sj.ki.5002040. View

Zhang S, Han C, Sun L, Huang L, Ma J . Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis. Radiat Oncol. 2020; 15(1):205. PMC: 7446219. DOI: 10.1186/s13014-020-01646-9. View

Zatloukal P, Petruzelka L, Zemanova M, Havel L, Janku F, Judas L . Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer. 2004; 46(1):87-98. DOI: 10.1016/j.lungcan.2004.03.004. View

Zhai Y, Ma H, Hui Z, Zhao L, Li D, Liang J . HELPER study: A phase II trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer. Radiother Oncol. 2019; 131:27-34. DOI: 10.1016/j.radonc.2018.10.032. View

10.

Devine A, Marignol L . Potential of Amifostine for Chemoradiotherapy and Radiotherapy-associated Toxicity Reduction in Advanced NSCLC: A Meta-Analysis. Anticancer Res. 2016; 36(1):5-12. View

11.

Herbst R, Arkenau H, Santana-Davila R, Calvo E, Paz-Ares L, Cassier P . Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. Lancet Oncol. 2019; 20(8):1109-1123. DOI: 10.1016/S1470-2045(19)30458-9. View

12.

Taylor M, Lee C, Makker V, Rasco D, Dutcus C, Wu J . Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors. J Clin Oncol. 2020; 38(11):1154-1163. PMC: 7145588. DOI: 10.1200/JCO.19.01598. View

13.

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

14.

Honglian M, Zhouguang H, Fang P, LuJun Z, Dongming L, Yujin X . Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non-small cell lung cancer: Updated follow-up results from two.... Thorac Cancer. 2020; 11(4):898-906. PMC: 7113061. DOI: 10.1111/1759-7714.13333. View

15.

Komaki R, Lee J, Kaplan B, Allen P, Kelly J, Liao Z . Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. Semin Radiat Oncol. 2002; 12(1 Suppl 1):46-9. DOI: 10.1053/srao.2002.31363. View

16.

Huang Y, Yuan J, Righi E, Kamoun W, Ancukiewicz M, Nezivar J . Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012; 109(43):17561-6. PMC: 3491458. DOI: 10.1073/pnas.1215397109. View

17.

Tsujino K, Hashimoto T, Shimada T, Yoden E, Fujii O, Ota Y . Combined analysis of V20, VS5, pulmonary fibrosis score on baseline computed tomography, and patient age improves prediction of severe radiation pneumonitis after concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer. J Thorac Oncol. 2014; 9(7):983-990. DOI: 10.1097/JTO.0000000000000187. View

18.

Antonadou D, Coliarakis N, Synodinou M, Athanassiou H, Kouveli A, Verigos C . Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys. 2001; 51(4):915-22. DOI: 10.1016/s0360-3016(01)01713-8. View

19.

Zhang K, Yang S, Zhu Y, Mo A, Zhang D, Liu L . Protection against acute radiation-induced lung injury: a novel role for the anti-angiogenic agent Endostar. Mol Med Rep. 2012; 6(2):309-15. DOI: 10.3892/mmr.2012.903. View

20.

Janssen-Heijnen M, van Erning F, de Ruysscher D, Coebergh J, Groen H . Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosis. Ann Oncol. 2015; 26(5):902-907. DOI: 10.1093/annonc/mdv061. View